REGN Regeneron Pharmaceuticals, Inc.
Five-factor quant read, peer ranking, and the analyst team's own call.
6.4
composite/ 10
Value
-
Quality
computed
6.7
Piotroski 4/8 · Altman safe zone · ROE 14% · interest comfortably covered
Momentum
rank
8.0
pressing its 52-week high · strong 3-month run
Defensive
rank
7.0
Tactical
rank
4.0
Descriptive, not predictive. Momentum, Defensive and Tactical are deciles within our liquid universe; Value and Quality are computed from filed financials. None of them forecasts a return - the model's out-of-sample AUC is published in the whitepaper. Deciles as of 2026-09-02.
Peer comparison
Composite score against sector peers · 1 names
REGN ranks #1 of 1 · peer average 6.4
No current desk call on REGN.
The factor scores above are computed; a full analysis is four analyst desks, a bull-vs-bear
debate and a risk committee, and takes about three minutes.
Automated, educational research - not investment advice, and not a recommendation to buy or sell any security.